Evidence map›Paper›PMID 39825426›Full record

Trial reportCritical care (London, England)2025

Cardiovascular effects of lactate in healthy adults.

Kristoffer Berg-Hansen, Nigopan Gopalasingam, Mette Glavind Bülow Pedersen, Jakob Tobias Nyvad, Nikolaj Rittig, Esben Søndergaard, Henrik Wiggers, Niels Møller, Roni Nielsen

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Critical care (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04710875 (The Role of Lactate in Lipolysis and Catabolism in Humans), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04710875 nacompletednot on this map

The Role of Lactate in Lipolysis and Catabolism in Humans

TypeinterventionalSponsorUniversity of AarhusRan2021 to 2021Enrolled8ConditionsHyperlactatemia, Healthy, LactateArmsNa-lactate, Sodium chloride
3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Kristoffer Berg-Hansen *Department of Cardiology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200, Aarhus N, Denmark. krisbe@rm.dk.
Nigopan Gopalasingam *Department of Cardiology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200, Aarhus N, Denmark.
Mette Glavind Bülow PedersenDepartment of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark.
Jakob Tobias NyvadDepartment of Cardiology, Gødstrup Hospital, Herning, Denmark.
Nikolaj RittigDepartment of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark.
Esben SøndergaardDepartment of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark.
Henrik WiggersDepartment of Cardiology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200, Aarhus N, Denmark.
Niels MøllerDepartment of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark.
Roni NielsenDepartment of Cardiology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200, Aarhus N, Denmark.

Funding

Danmarks Frie Forskningsfond 8020-00120AHjerteforeningen 19-R135-A9280-22126Lundbeck Foundation R231-2016-2716Novo Nordisk Fonden NNF17OC0028230Novo Nordisk Fonden NNF19OC0055002
6 · The paper itself

Abstract

backgroundLow-volume hypertonic solutions, such as half-molar lactate (LAC), may be a potential treatment used for fluid resuscitation. This study aimed to evaluate the underlying cardiovascular effects and mechanisms of LAC infusion compared to sodium-matched hypertonic sodium chloride (SAL).

methodsEight healthy male participants were randomized in a controlled, single-blinded, crossover study. Each participant received a four-hour infusion of LAC and SAL in a randomized order. Assessor-blinded echocardiography and blood samples were performed. The primary endpoint was cardiac output (CO) measured by echocardiography.

resultsDuring LAC infusion, circulating lactate levels increased by 1.9 mmol/L (95% CI 1.8-2.0 mmol/L, P < 0.001) compared with SAL. CO increased by 1.0 L/min (95% CI 0.5-1.4 L/min, P < 0.001), driven primarily by a significant increase in stroke volume of 11 mL (95% CI 4-17 mL, P = 0.002), with no significant change in heart rate. Additionally, left ventricular ejection fraction improved by 5 percentage points (P < 0.001) and global longitudinal strain by 1.5 percentage points (P < 0.001). Preload indicators were elevated during SAL infusion compared with LAC infusion. Concomitantly, afterload parameters, including systemic vascular resistance and effective arterial elastance, were significantly decreased with LAC infusion compared with SAL, while mean arterial pressure remained similar. Indicators of contractility improved during LAC infusion.

conclusionsIn healthy participants, LAC infusion enhanced cardiac function, evidenced by increases in CO, stroke volume, and left ventricular ejection fraction compared with SAL. Indicators of contractility improved, afterload decreased, and preload remained stable. Therefore, LAC infusion may be an advantageous resuscitation fluid, particularly in patients with cardiac dysfunction. CLINICAL TRIAL REGISTRATIONS: https://clinicaltrials.gov/ct2/show/NCT04710875 . Registered 1 December 2020.

Indexed as

Lactic AcidAdultCardiac OutputCross-Over StudiesEchocardiographyFluid TherapyHealthy VolunteersHeart RateHumansMaleSaline Solution, HypertonicSingle-Blind MethodStroke VolumeLactic AcidSaline Solution, HypertonicAfterloadCardiac outputEchocardiographyLactateLeft ventricular ejection fractionPreload

Identifiers

PMID39825426
PMCPMC11740418

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.